51 results about "Antigen binding site" patented technology

The present invention relates to: a receptor tyrosine kinase like orphan receptor 1 (ROR 1) antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector carrying the nucleic acid; a host cell transinfected with the recombinant expression vector; a method for preparing the antibody or the antigen-binding fragment thereof; a bi- or multi-specific antibody bearing the antibody or the antigen-binding fragment thereof; an immune cell-engaging bi- or multi-specific antibody; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) containing the scFv of the antibody as an antigen-binding site of an extracellular domain; an immune cell having the chimeric antigen receptor introduced thereinto; a composition for combination therapy including the antibody or the antigen-binding fragment thereof; a composition for preventing or treating cancer; and a method for preventing or treating cancer.

Provided herein are compositions comprising trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and / or trivalent binding proteins and uses of such binding proteins for the treatment and / or prevention of HIV / AIDS.

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

Disclosed herein are methods of treating autoimmune, allergic, and / or inflammatory diseases in a subject in need thereof, comprising administering a therapeutic agent comprising one or more antigen-binding sites on a cell involved in the autoimmune, allergic, and / or inflammatory diseases and depleting the cell.

The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

The present application relates to antibody molecules that bind both PD-L1 and CD137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.

Novel compounds are disclosed that contain two antigen-binding sites and a tetramerization site, where the antigen-binding sites are selected from naturally occurring binding sites. The novel compounds have improved manufacturability, stability, and solubility compared to similar compounds based on scFv binding sites, making the disclosed compounds much better candidates for active ingredients in pharmaceutical compositions.

The problem to be solved by the present invention is to provide more and better options for treating any solid tumor with high frequency microsatellite instability (high frequency MSI or MSI-H) alterations, cervical cancer, endometrial cancer, lung cancer, brain cancer and breast cancer.SOLUTION: The present invention relates to multispecific antibodies comprising an antigen binding site that binds an extracellular part of CD137 and an antigen binding site that binds an extracellular part of a second membrane protem for use in a method of treatment of cancers in a subject in need thereof. The invention further relates to such multispecific antibodies, as well as methods and other aspects related thereto.SELECTED DRAWING: None

The invention relates to a bispecific antibody or an antigen-binding fragment thereof comprising a first antigen binding site that can bind to TIGIT and a second antigen binding site that can bind to 4-1BB; pharmaceutical compositions comprising such bispecific antibodies and uses thereof. In particular, the antibody or the antigen-binding fragment thereof or the bispecific antibody or an antigen-binding fragment thereof can cause activation of T cells and then it can effectively prevent or treat the cancer.

The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Anti-CD47 / anti-TIGIT bispecific antibody, a preparation method thereof and application thereof. The bispecific antibody comprises: (a) a first antigen binding part, comprising heavy chain variable region (VH) and light chain variable region (VL), VH and VL forming an antigen binding site that specifically binds to CD47; and (b) a second antigen binding part, comprising a single domain antibody (sdAb) that specifically binds to TIGIT, wherein the first antigen binding part and the second antigen binding part are fused with each other. The bispecific antibody can block two modes of tumor immune escape at the same time, thus having a good effect in tumor immunotherapy.

The present invention improves an effect of killing or an effect of inhibiting the growth of cancer cells. The present invention comprises: a binding domain that includes a first antigen-binding site that binds to a cancer cell and a second antigen-binding site that binds to a T cell; a cleavable sequence that is linked to the binding domain; and a masking moiety that is linked to the N-terminus of a single-chain antibody via the cleavable sequence when the binding domain is composed of the single-chain antibody, and that is linked to the C-terminus of each light chain via the cleavable sequence when the binding domain is composed of heavy chains and light chains. In a state in which the cleavable sequence is cleaved, the masking moiety functions as an agonist of a co-stimulatory molecule for the T cell or an antagonist of a co-inhibitory molecule for the T cell.

The application belongs to the technical field of bioengineering, and particularly relates to a monoclonal antibody against canine IFN-alpha and application thereof. The monoclonal antibody comprises a monoclonal antibody 1C1 or an antigen binding site thereof and a monoclonal antibody 2A4 or an antigen binding site thereof, and the monoclonal antibody and the antibody combination thereof are carefully screened and optimized, can be used for detection of canine interferon, and have extremely high specificity and sensitivity. An ELISA kit developed by the antibody combination not only simplifies a detection process, but also improves detection efficiency. The capture antibody and the detection antibody in the kit can synergistically act, can realize high-precision detection of the canine interferon, are not only high in detection sensitivity, but also excellent in specificity, effectively avoid interference of non-specific reactions. The technical breakthrough exhibits broad development potential and practical application prospect, and provides a powerful tool for canine health monitoring, disease diagnosis and related research.

The application relates to the technical field of antibodies, in particular to an anti-idiotypic antibody specifically binding to a CAR antigen binding site, which has the advantages of high affinity, high specificity and no non-specific background, and is more suitable for evaluating the CAR transfection positive rate and the change rule of the number of CAR positive T cells in a subject after administration.

The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.

To provide a set of antibodies that bind to an antigen on a target cell and target a radionuclide to the cell, and an agent comprising the set of antibodies.SOLUTION: I) a first antibody that binds to an antigen expressed on the surface of a target cell, wherein said first antibody further comprises a VH domain of a functional antigen binding site for a radiolabeled compound, but does not comprise a VL domain of a functional antigen binding site for a radiolabeled compound; and ii) a second antibody that binds to said antigen expressed on the surface of a target cell, wherein said second antibody comprises: A second antibody which further comprises a VL domain of a functional antigen binding site for a radiolabelled compound, but does not comprise a VH domain of a functional antigen binding site for a radiolabelled compound; wherein said VH domain of the first antibody and said VL domain of the second antibody are capable of together forming a functional antigen binding site for a radiolabelled compound.SELECTED DRAWING: Figure 1

Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subjects with hidradenitis suppurativa. Further disclosed are T cells, and in particular, Treg cells that express these CARs. Administration of these CAR-T cells is useful in the treatment of hidradenitis suppurativa.

The present disclosure provides method of treating a subject having a cancer comprising administering to the subject about 0.2 pg to about 4500 pg of a trispecific binding protein, wherein the trispecific binding protein comprises a first antigen binding site that binds a CD28 polypeptide, a second antigen binding site that binds a CD3 polypeptide, and a third antigen binding site that binds a HER2 polypeptide.

The instant disclosure provides proteins with antibody heavy chain variable domains and light chain variable domains that can be paired to form antigen-binding sites that specifically bind to PD-L1. In certain embodiments, the proteins or antigen-binding sites form antibody or bispecific antibody, such as, for example, PD-L1 / IL-2Rβ bispecific antibody. Also provided are pharmaceutical compositions comprising such proteins, therapeutic methods for using such proteins, and pharmaceutical compositions thereof, including for the treatment of cancer.

The present invention provides CAR-T cells constructed based on the natural protein TSH. The present invention also provides chimeric antigen receptor (TAR) CAR-T cells constructed based on the tandem structure of the TSH α and β subunits, and uses thereof. The TSHαβ-CAR-T cells of the present invention can target and kill TSHR-positive thyroid cancer cells and are non-immunogenic, making them promising candidates for the treatment of thyroid cancer.

The present disclosure relates generally to binding proteins comprising an antigen binding site, a T cell receptor binding site, and a T cell costimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins and vectors comprising such nucleic acid molecules. The disclosure also relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for the treatment of a disorder or condition.

The present invention provides a chimeric antigen-receptor targeting LRRC15, which exhibits drug efficacy against tumors associated with LRRC15 positive cells, and cells comprising the same.SOLUTION: To provide a chimeric antigen-binding receptor containing an anti- LRRC15 antigen-binding site containing a specific CDR, and to provide chimeric antigen-binding receptor-expressing cells containing the receptor.SELECTED DRAWING: None

To provide an alternative antibody therapy targeting glycan epitopes.SOLUTION: Provided is an antibody or antigen-binding portion thereof that binds to sialyl Lewis A (sLeA) and sialyl Lewis C (sLeC), wherein the binding affinity of the antibody or antigen-binding portion to sLeA is a KD of 60 μ M or less and the binding affinity to sLeC is a KD of 100 μ M or less. Also provided are polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.SELECTED DRAWING: Figure 2C

Provided herein are trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and the three antigen binding sites specifically bind an interleukin-4 (IL-4) polypeptide, an interleukin-13 (IL-13) polypeptide, and a polypeptide expressed on the surface of a cytotoxic lymphocyte (e.g., a natural killer (NK) cell, CD4+ T cells, CD8+ αβ T cells and γδ T cells), respectively. The disclosure also relates to nucleic acid molecules, expression vectors, host cells, compositions (e.g., pharmaceutical compositions), methods of production, methods of use, and uses related thereto.

Provided herein are trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and at least two of the antigen binding sites specifically bind an interleukin-4 (IL-4) polypeptide and an interleukin-13 (IL-13) polypeptide, respectively. In some embodiments, the third antigen binding site specifically binds an OX40L polypeptide. The disclosure also relates to nucleic acid molecules, expression vectors, host cells, compositions (e.g., pharmaceutical compositions), methods of production, methods of use, and uses related thereto.

To provide means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell, and to provide binding molecules such as antibodies that comprises at least two antigen binding sites, where a first antigen binding site can bind an extracellular part of said member and a second antigen binding site can bind an extracellular part of a second (different) membrane protein.SOLUTION: There is provided a method of stimulating activity of a member of the TNF receptor superfamily on a cell comprising providing a first cell and a second cell. The first cell has the member on the cell membrane and the second cell has a second membrane protein on the cell membrane, the method comprising contacting the cells with a bispecific antibody that comprises two variable domains. Here, one variable domain comprises a first antigen binding site that can bind an extracellular part of the member and another variable domain comprises a second antigen binding site that can bind an extracellular part of' the second membrane protein, thereby stimulating activity of the member on the first cell.SELECTED DRAWING: None

The invention discloses a histioplasma capsulatum double-antibody sandwich enzyme-linked immunosorbent assay method, a reagent and application. The invention relates to the technical field of ELISA (enzyme-linked immunosorbent assay). According to the present invention, the Protein A / G magnetic beads are used to directionally fix the antibody and ultrasonically assist the antigen release, such that the antigen binding site is completely exposed, and the hidden antigen is released, such that the test sensitivity is significantly improved, the sensitivity can be improved by 10 times, and the detection limit is reduced to the lower level (such as 1 ng / mL or even 0.1 ng / mL). Due to the use of the block copolymer / zwitterionic surfactant, non-specific binding is effectively blocked, background signals are reduced, and the test specificity is improved; the method comprises the following steps: S1, antibody coating: diluting a captured antibody to a working concentration (generally 1-10 [mu] g / mL) by using a coating buffer solution, and adding into an ELISA plate hole (100 [mu] L / hole); carrying out overnight incubation at 4 DEG C (or at 37 DEG C for 2h) after plate sealing; and discarding the liquid, and washing with PBST for 3 times (300 [mu] L / hole, and drying after standing for 1 min each time). Protein A / G magnetic beads are used for directionally fixing the antibody through an Fc segment.

The present invention provides a multispecific antibody having at least one conditional activity and a method for producing the same. [Solution] A multispecific antibody comprises at least one binding site for a cell-specific antigen and at least one binding site for a tumor-reactive lymphocyte antigen, and the multispecific antibody comprises an IgG antibody or fragment thereof that binds to a first antigen; and at least one scFv antibody that binds to a second antigen different from the first antigen and is ligated to the C-terminus of at least one light chain or heavy chain of the IgG antibody or fragment. This multispecific antibody reversibly binds to the cell-specific antigen and the tumor-reactive lymphocyte antigen or at least one of the first antigen and the second antigen with greater affinity under abnormal conditions than under normal physiological conditions. Conjugates of multispecific antibodies and methods for producing multispecific antibodies are also provided.

This provides antibodies usable in pre-targeted radioimmunotherapy (PRIT) and radioimmunoimaging. [Solution] A multispecific antibody is provided for use in therapy, comprising an antigen-binding site specific to DOTAM-lead (Pb) chelate and an antigen-binding site specific to a target antigen.